Production (Stage)
Lotus Pharmaceuticals, Inc.
LTUS
$0.005
-$0.0009-15.25%
OTC PK
| 09/30/2011 | 06/30/2011 | ||||
|---|---|---|---|---|---|
| Revenue | 1.87% | 44.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.87% | 44.72% | |||
| Cost of Revenue | 13.93% | 104.12% | |||
| Gross Profit | -32.19% | -20.57% | |||
| SG&A Expenses | -34.56% | -24.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.15% | 58.48% | |||
| Operating Income | -29.07% | -20.51% | |||
| Income Before Tax | -29.34% | -20.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.34% | -20.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.34% | -20.64% | |||
| EBIT | -29.07% | -20.51% | |||
| EBITDA | -23.66% | -17.25% | |||
| EPS Basic | -29.47% | -21.14% | |||
| Normalized Basic EPS | -29.50% | -21.26% | |||
| EPS Diluted | -29.43% | -21.39% | |||
| Normalized Diluted EPS | -29.37% | -21.47% | |||
| Average Basic Shares Outstanding | 0.14% | 0.93% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||